The objective of this study was to investigate real-world EGFR mutation testing in patients with metastatic non-small cell lung cancer (NSCLC) upon progression on first−/second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI), and subsequent treatments received. | EGFR mutation testing and treatment decisions in patients progressing on firstor second-generation epidermal growth factor receptor tyrosine kinase inhibitors